Durvalumab: Phase II started

TapImmune Inc. (OTCQB:TPIV, Jacksonville, Fla.) and AstraZeneca began an open-label, U.S. Phase II trial to evaluate intradermal TPIV200 on day 1 of each 4-week cycle for the first 6 cycles plus IV ...